ArticleNeuro-oncology advances

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Byram H Ozer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.